All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Human Immune Globulin
Therapeutic Area: Infections and Infectious Diseases Product Name: Octagam
Highest Development Status: Phase IV Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
Details:
The data shows that IVIG treatment reduces inflammation, which is associated with poor clinical outcomes and death, and points to an increase in survival, in critically ill COVID-19 patients, when compared to a control group.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Human Immune Globulin
Therapeutic Area: Infections and Infectious Diseases Product Name: Octagam
Highest Development Status: Phase IV Product Type: Large molecule
Partner/Sponsor/Collaborator: University of California San Diego School of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding June 03, 2020
Details:
The randomized open label study is evaluating the standard of care (SOC) plus intravenous immunoglobulin (IVIG) compared to SOC alone in the treatment of COVID-19 infection, specifically in preventing mechanical ventilation in COVID-19 patients requiring high-flow oxygen.